These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8332999)

  • 1. Effect of moricizine on the pharmacokinetics of single-dose theophylline in healthy subjects.
    Pieniaszek HJ; Davidson AF; Benedek IH
    Ther Drug Monit; 1993 Jun; 15(3):199-203. PubMed ID: 8332999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic comparison of a once-daily and twice-daily theophylline delivery system.
    González MA; Kisicki J; Straughn AB
    Clin Ther; 1994; 16(4):686-92. PubMed ID: 7982257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl.
    Hurwitz A; Karim A; Burns TS
    J Clin Pharmacol; 1987 Nov; 27(11):855-61. PubMed ID: 3429692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single-dose comparison of three slow-release theophylline oral preparations in healthy Thai volunteers.
    Kanthawatana S; Tontayapiwat A; Tonsuwannont W; Manorot M
    Asian Pac J Allergy Immunol; 1996 Jun; 14(1):13-8. PubMed ID: 8980795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theophylline absorption from two sustained-release products. Implications for therapeutic drug monitoring.
    Rogers RJ; Wiener MB; Hill MR; Szefler SJ
    Am Rev Respir Dis; 1987 Nov; 136(5):1168-73. PubMed ID: 3674579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium.
    Rojanasthien N; Kovjiriyapan K; Manorot M; Pothirat C
    Asian Pac J Allergy Immunol; 2001 Jun; 19(2):69-78. PubMed ID: 11699723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of a modified starch hydrophilic matrix for the sustained release of theophylline in healthy volunteers.
    Vandenbossche GM; Lefebvre RA; De Wilde GA; Remon JP
    J Pharm Sci; 1992 Mar; 81(3):245-8. PubMed ID: 1640362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic interactions of moricizine and diltiazem in healthy volunteers.
    Shum L; Pieniaszek HJ; Robinson CA; Davidson AF; Widner PJ; Benedek IH; Flamenbaum W
    J Clin Pharmacol; 1996 Dec; 36(12):1161-8. PubMed ID: 9013374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of the pharmacokinetic characteristics of slow release theophylline oral preparations in Thai children with persistent asthma.
    Trakultivakorn M; Kanthawatana S; Tontayapiwat A; Jiraporncharoen K
    Asian Pac J Allergy Immunol; 1999 Dec; 17(4):255-9. PubMed ID: 10698464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic analysis of sustained-release dosage forms of theophylline in humans: comparison of single and multiple dose studies.
    Hussein Z; Bialer M; Friedman M; Raz I
    Biopharm Drug Dispos; 1987; 8(5):427-35. PubMed ID: 3663879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption of theophylline from enteric coated and sustained release formulations in fasted and non-fasted subjects.
    Osman MA; Patel RB; Irwin DS; Welling PG
    Biopharm Drug Dispos; 1983; 4(1):63-72. PubMed ID: 6839003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose proportionality of moricizine after escalating multiple doses in healthy volunteers.
    Benedek IH; Garner DM; Pieniaszek HJ
    J Clin Pharmacol; 1991 Mar; 31(3):229-32. PubMed ID: 2019664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Theophylline QID, TID, BID and now QD? A report on 24-hour dosing with slow-release theophylline formulations with emphasis on analyses of data used to obtain Food and Drug Administration approval for Theo-24.
    Weinberger MM
    Pharmacotherapy; 1984; 4(4):181-98. PubMed ID: 6483637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability of four slow-release theophylline formulations in the beagle dog.
    Koritz GD; McKiernan BC; Neff-Davis CA; Munsiff IJ
    J Vet Pharmacol Ther; 1986 Sep; 9(3):293-302. PubMed ID: 3761420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioequivalence of a generic slow-release theophylline tablet in children.
    Kanthawatana S; Ahrens RC; McCubbin M; Bronsky E; Blake K; Hendeles L
    J Pediatr; 1994 Dec; 125(6 Pt 1):987-91. PubMed ID: 7996375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The rise and fall of serum theophylline concentration: a comparison of sustained-release formulations in volunteers with rapid theophylline clearance.
    Mucklow JC; Kuhn S
    Br J Clin Pharmacol; 1985 Dec; 20(6):589-96. PubMed ID: 4091990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption of theophylline from a sustained-release theophylline tablet formulation, Theo-Dur.
    Takagi K; Hasegawa T; Ogura Y; Yamaki K; Suzuki R; Satake T; Imaeda N; Mizukami Y
    Int J Clin Pharmacol Ther Toxicol; 1987 Oct; 25(10):530-5. PubMed ID: 3429057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of hyperlipidic food on the kinetics of slow-release formulations of theophylline.
    Brazier JL; Benchekroun Y; Gillet A; Andre C
    Eur J Clin Pharmacol; 1989; 37(1):85-90. PubMed ID: 2591470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative steady-state bioavailability of Theo-24 and Theo-Dur in healthy men.
    Dockhorn RJ; Cefali EA; Straughn AB
    Ann Allergy; 1994 Mar; 72(3):218-22. PubMed ID: 8129214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Release and absorption characteristics of novel theophylline sustained-release formulations: in vitro-in vivo correlation.
    Hussein Z; Friedman M
    Pharm Res; 1990 Nov; 7(11):1167-71. PubMed ID: 2293217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.